---
title: "Spyre Therapeutics Announces Grants of Inducement Awards"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291586575.md"
description: "Spyre Therapeutics announced that its Compensation Committee approved inducement awards consisting of 58,843 stock options and 2,134 restricted stock units (RSUs) for six non-executive employees. Granted under the 2018 Equity Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4), these awards aim to facilitate recruitment and support the company's mission to enhance immunology treatments."
datetime: "2026-07-02T20:12:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291586575.md)
  - [en](https://longbridge.com/en/news/291586575.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291586575.md)
---

# Spyre Therapeutics Announces Grants of Inducement Awards

On July 2, 2026, Spyre Therapeutics, Inc. (NASDAQ: SYRE) based in Waltham, Massachusetts, disclosed that their Compensation Committee approved the issuance of stock options for the purchase of a total of 58,843 common shares and 2,134 restricted stock units (RSUs) to six non-executive staff members. These equity inducement awards were granted under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan and were considered crucial for the employees' recruitment as per Nasdaq Listing Rule 5635(c)(4). This move aims to enhance the standard of immunology treatments by offering more comprehensive disease management, improved longevity, and a more convenient therapy process for patients.

### Related Stocks

- [SYRE.US](https://longbridge.com/en/quote/SYRE.US.md)

## Related News & Research

- [Spyre Therapeutics grants inducement equity awards to four new hires at $94.93 strike price](https://longbridge.com/en/news/295272795.md)
- [Spyre Therapeutics director Jeffrey W. Albers disposes of USD 2.39 million in common shares](https://longbridge.com/en/news/295470041.md)
- [Spyre Therapeutics Q2 loss narrower than expected; sees trial readouts in 2026](https://longbridge.com/en/news/294864706.md)
- [Spyre Therapeutics: Merck TL1A Readthrough Supports Multi-Disease Opportunity, Solid Cash Runway, and Unchanged $119 Buy Target](https://longbridge.com/en/news/294870016.md)
- [Realtor.com names Peabody, Massachusetts top US “hottest” ZIP code for 2026 housing demand](https://longbridge.com/en/news/295388430.md)